A comparative analysis of recurrence risk predictions in ER+/HER2− early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast

AIMS: Clinicians use multi-gene/biomarker prognostic tests and free online tools to optimize treatment in early ER+/HER2− breast cancer. Here we report the comparison of recurrence risk predictions by CanAssist Breast (CAB), Nottingham Prognostic Index (NPI), and PREDICT along with the differences i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunda, Aparna, Eshwaraiah, Mallikarjuna S., Gangappa, Kiran, Kaur, Taranjot, Bakre, Manjiri M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581859/
https://www.ncbi.nlm.nih.gov/pubmed/36085534
http://dx.doi.org/10.1007/s10549-022-06729-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581859/
https://www.ncbi.nlm.nih.gov/pubmed/36085534
http://dx.doi.org/10.1007/s10549-022-06729-7

Ejemplares similares